Clinical Trial Update: Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial evaluating Glembatumumab Vedotin in gpNMB-expressing advanced or metastatic squamous cell carcinoma of the lung has been terminated with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Lung

Drugs mentioned

• Glembatumumab Vedotin (glembatumumab vedotin)

Snippet

Sponsor: PrECOG, LLC. | Conditions: Squamous Cell Carcinoma of the Lung | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2019-07-16